High response rates, long-term remissions in Penn trials of personalized cell therapy

Ninety-three percent of pediatric patients (55 of 59) with relapsed/refractory acute lymphoblastic leukemia (ALL) went into remission after receiving an investigational therapy made from their own… Source link